Wide Ranks

ESPR

Esperion Therapeutics, Inc.

2.54

Top Statistics
Market Cap 500 M Forward PE 7.66 Revenue Growth 52.00 %
Current Ratio 1.85 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -29.37 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 37.87 Enterprise / Revenue 2.11 Price To Sales Trailing12 Months 1.69
Profitability
Profit Margins -29.37 % Operating Margins -31.04 %
Balance Sheet
Total Cash 144 M Total Cash Per Share 0.7340 Total Debt 268 M
Total Debt To Equity Current Ratio 1.85 Book Value Per Share -1.89
All Measures
Short Ratio 699.00 % Message Board Id finmb_28236 Shares Short Prior Month 35 M
City Ann Arbor Uuid 00314c6d-38c1-3c8e-a318-bd51d9ba1c8c Previous Close 2.57
First Trade Date Epoch Utc 1 B Book Value -1.89 Beta 0.9540
Total Debt 268 M Volume 5 M Fifty Two Week Low 1.27
Total Cash Per Share 0.7340 Total Revenue 295 M Shares Short Previous Month Date 1 B
Target Median Price 6.50 Max Age 86400 Recommendation Mean 2.14
Sand P52 Week Change 0.3133 Operating Margins -31.04 % Target Mean Price 7.51
Net Income To Common -86771000 Short Percent Of Float 0.1590 Implied Shares Outstanding 197 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 5 M
Average Volume10days 5 M Total Cash 144 M Next Fiscal Year End 1 B
Revenue Per Share 1.78 Held Percent Insiders 0.0050 Ebitda Margins 5.58 %
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 2.57 Target Low Price 2.05 Gmt Off Set Milliseconds -18000000
Fifty Day Average 2.08 Open 2.59 Free Cashflow -8951375
State MI Dividend Yield 0.00 % Return On Assets 0.0384
Time Zone Short Name EST Trailing Eps -0.6700 Day Low 2.46
Address1 3891 Ranchero Drive Shares Outstanding 197 M Price Hint 4
Target High Price 16.00 Website https://www.esperion.com 52 Week Change 0.9098
Average Volume 3 M Forward Eps 0.2000 Recommendation Key buy
Compensation As Of Epoch Date 1 B Quick Ratio 128.10 % Is_sp_500 False
Regular Market Day High 2.61 Profit Margins -29.37 % Fifty Two Week High 3.40
Day High 2.61 Shares Short 31 M Regular Market Open 2.59
Industry Key drug-manufacturers-specialty-generic Earnings Growth 0.00 % Enterprise To Revenue 2.11
Revenue Growth 52.00 % Shares Percent Shares Out 0.1586 Operating Cashflow -25758000
Currency USD Time Zone Full Name America/New_York Market Cap 500 M
Is_nasdaq_100 False Zip 48108 Quote Type EQUITY
Industry Drug Manufacturers - Specialty & Generic Long Name Esperion Therapeutics, Inc. Regular Market Day Low 2.46
Held Percent Institutions 0.6633 Current Price 2.54 Address2 Suite 150
Enterprise To Ebitda 37.87 Financial Currency USD Current Ratio 1.85
Gross Margins 63.64 % Industry Disp Drug Manufacturers - Specialty & Generic Number Of Analyst Opinions 6
Country United States Float Shares 195 M Two Hundred Day Average 2.22
Enterprise Value 624 M Price To Sales Trailing12 Months 1.69 Forward PE 7.66
Regular Market Volume 5 M Ebitda 16 M Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C).

Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.

The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C.

The company has license and collaboration agreements with Daiichi Sankyo Co.

Ltd to; Otsuka Pharmaceutical Co.

, Ltd; and Daiichi Sankyo Europe GmbH.

Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.